World first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in men

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved trofolastat (RoTecPSMA), the first prostate-specific membrane antigen (PSMA)-targeting product authorised for use with technetium-99m to detect cancerous lesions in men…

Continue ReadingWorld first as MHRA approves trofolastat for diagnostic imaging of prostate cancer in men